Cellectar Biosciences, Inc. Cash and Cash Equivalents, Period Increase (Decrease)
Cellectar Biosciences, Inc. (CLRB) reported Cash and Cash Equivalents, Period Increase (Decrease) of -$1.44 million for the 12-month period ending 2017-12-31, per its 10-K filed 2018-03-21.
Discontinued › Cash Flow
us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease · last filed 2018-03-21
- Cellectar Biosciences, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-12-31 was $4.34M, a 25.08% decline year-over-year.
- Cellectar Biosciences, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-09-30 was -$2.65M.
- Cellectar Biosciences, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-06-30 was -$2.93M, a 148.64% decline year-over-year.
- Cellectar Biosciences, Inc. cash and cash equivalents, period increase (decrease) for the quarter ending 2017-03-31 was -$206.22K.
- Cellectar Biosciences, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2017 was -$1.44M, a 118.96% decline from fiscal 2016.
- Cellectar Biosciences, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2016 was $7.59M.
- Cellectar Biosciences, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2015 was -$5.56M, a 179.45% decline from fiscal 2014.
- Cellectar Biosciences, Inc. cash and cash equivalents, period increase (decrease) for fiscal 2014 was $7.00M.
| Period end | Cash and Cash Equivalents, Period Increase (Decrease) 3 month | Cash and Cash Equivalents, Period Increase (Decrease) 6 month | Cash and Cash Equivalents, Period Increase (Decrease) 9 month | Cash and Cash Equivalents, Period Increase (Decrease) 12 month | Cash and Cash Equivalents, Period Increase (Decrease) 104 month | Cash and Cash Equivalents, Period Increase (Decrease) 107 month | Cash and Cash Equivalents, Period Increase (Decrease) 110 month | Cash and Cash Equivalents, Period Increase (Decrease) 113 month | Cash and Cash Equivalents, Period Increase (Decrease) 116 month | Cash and Cash Equivalents, Period Increase (Decrease) 119 month | Cash and Cash Equivalents, Period Increase (Decrease) 122 month | Cash and Cash Equivalents, Period Increase (Decrease) 125 month | Cash and Cash Equivalents, Period Increase (Decrease) 128 month | Cash and Cash Equivalents, Period Increase (Decrease) 131 month | Cash and Cash Equivalents, Period Increase (Decrease) 134 month | Cash and Cash Equivalents, Period Increase (Decrease) 137 month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2017-12-31 | $4.34M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-21 | $1.69M derived: sum of 2 quarters · filed 2018-03-21 | -$1.23M derived: sum of 3 quarters · filed 2018-03-21 | -$1.44M 10-K · filed 2018-03-21 | ||||||||||||
| 2017-09-30 | -$2.65M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | -$5.58M derived: sum of 2 quarters · filed 2017-11-09 | -$5.78M 10-Q · filed 2017-11-09 | $16.26K derived: sum of 4 quarters · filed 2018-03-21 | ||||||||||||
| 2017-06-30 | -$2.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | -$3.13M 10-Q · filed 2017-08-14 | $2.67M derived: sum of 3 quarters · filed 2018-03-21 | $390.93K derived: sum of 4 quarters · filed 2018-03-21 | ||||||||||||
| 2017-03-31 | -$206.22K 10-Q · filed 2017-05-11 | $5.59M derived: sum of 2 quarters · filed 2018-03-21 | $3.32M derived: sum of 3 quarters · filed 2018-03-21 | $9.33M derived: sum of 4 quarters · filed 2018-03-21 | ||||||||||||
| 2016-12-31 | $5.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-21 | $3.52M derived: sum of 2 quarters · filed 2018-03-21 | $9.54M derived: sum of 3 quarters · filed 2018-03-21 | $7.59M 10-K · filed 2018-03-21 | ||||||||||||
| 2016-09-30 | -$2.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $3.74M derived: sum of 2 quarters · filed 2017-11-09 | $1.79M 10-Q · filed 2017-11-09 | $3.17M derived: sum of 4 quarters · filed 2017-11-09 | ||||||||||||
| 2016-06-30 | $6.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-14 | $4.06M 10-Q · filed 2017-08-14 | $5.45M derived: sum of 3 quarters · filed 2017-08-14 | $3.09M derived: sum of 4 quarters · filed 2017-08-14 | ||||||||||||
| 2016-03-31 | -$1.95M 10-Q · filed 2017-05-11 | -$564.15K derived: sum of 2 quarters · filed 2017-05-11 | -$2.92M derived: sum of 3 quarters · filed 2017-05-11 | -$5.12M derived: sum of 4 quarters · filed 2017-05-11 | ||||||||||||
| 2015-12-31 | $1.39M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | -$975.49K derived: sum of 2 quarters · filed 2017-03-15 | -$3.17M derived: sum of 3 quarters · filed 2017-03-15 | -$5.56M 10-K · filed 2017-03-15 | ||||||||||||
| 2015-09-30 | -$2.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10 | -$4.56M derived: sum of 2 quarters · filed 2016-11-10 | -$6.95M 10-Q · filed 2016-11-10 | -$9.10M derived: sum of 4 quarters · filed 2016-11-10 | ||||||||||||
| 2015-06-30 | -$2.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11 | -$4.59M 10-Q · filed 2016-08-11 | -$6.74M derived: sum of 3 quarters · filed 2016-10-20 | $3.21M derived: sum of 4 quarters · filed 2016-10-20 | ||||||||||||
| 2015-03-31 | -$2.39M 10-Q · filed 2016-05-12 | -$4.55M derived: sum of 2 quarters · filed 2016-10-20 | $5.40M derived: sum of 3 quarters · filed 2016-10-20 | $3.22M derived: sum of 4 quarters · filed 2016-10-20 | ||||||||||||
| 2014-12-31 | -$2.15M derived: 10-K/A 12 month − 10-Q 9 month · filed 2016-10-20 | $7.80M derived: sum of 2 quarters · filed 2016-10-20 | $5.61M derived: sum of 3 quarters · filed 2016-10-20 | $7.00M 10-K/A · filed 2016-10-20 | ||||||||||||
| 2014-09-30 | $9.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-12 | $7.77M derived: sum of 2 quarters · filed 2015-11-12 | $9.16M 10-Q · filed 2015-11-12 | $6.47M derived: sum of 4 quarters · filed 2015-11-12 | ||||||||||||
| 2014-06-30 | -$2.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-12 | -$792.36K 10-Q · filed 2015-08-12 | -$3.48M derived: sum of 3 quarters · filed 2015-08-12 | -$4.20M derived: sum of 4 quarters · filed 2015-08-12 | ||||||||||||
| 2014-03-31 | $1.39M 10-Q · filed 2015-05-20 | -$1.30M derived: sum of 2 quarters · filed 2015-05-20 | -$2.02M derived: sum of 3 quarters · filed 2015-05-20 | -$4.05M derived: sum of 4 quarters · filed 2015-05-20 | $3.81M 10-Q · filed 2014-05-14 | |||||||||||
| 2013-12-31 | -$2.69M derived: 10-K 12 month − 10-Q 9 month · filed 2015-05-20 | -$3.41M derived: sum of 2 quarters · filed 2015-05-20 | -$5.44M derived: sum of 3 quarters · filed 2015-05-20 | -$2.26M 10-K · filed 2015-05-20 | $2.42M 10-K · filed 2014-03-19 | |||||||||||
| 2013-09-30 | -$717.76K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-05-20 | -$2.75M derived: sum of 2 quarters · filed 2015-05-20 | $432.95K 10-Q · filed 2015-05-20 | -$487.27K derived: sum of 4 quarters · filed 2015-05-20 | $5.11M 10-Q · filed 2013-11-13 | |||||||||||
| 2013-06-30 | -$2.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-04 | $1.15M 10-Q · filed 2014-08-04 | $230.49K derived: sum of 3 quarters · filed 2014-08-04 | -$1.32M derived: sum of 4 quarters · filed 2014-08-04 | $5.83M 10-Q · filed 2013-08-12 | |||||||||||
| 2013-03-31 | $3.18M 10-Q · filed 2014-05-14 | $2.26M derived: sum of 2 quarters · filed 2014-05-14 | $716.08K derived: sum of 3 quarters · filed 2014-05-14 | $4.07M derived: sum of 4 quarters · filed 2014-05-14 | $7.86M 10-Q · filed 2013-05-15 | |||||||||||
| 2012-12-31 | -$920.22K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-19 | -$2.47M derived: sum of 2 quarters · filed 2014-03-19 | $889.97K derived: sum of 3 quarters · filed 2014-03-19 | -$828.41K 10-K · filed 2014-03-19 | $4.68M 10-K · filed 2013-03-28 | |||||||||||
| 2012-09-30 | -$1.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-13 | $1.81M derived: sum of 2 quarters · filed 2013-11-13 | $91.80K 10-Q · filed 2013-11-13 | $4.01M derived: sum of 4 quarters · filed 2013-11-13 | $5.60M 10-Q · filed 2012-11-06 | |||||||||||
| 2012-06-30 | $3.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-12 | $1.64M 10-Q · filed 2013-08-12 | $5.56M derived: sum of 3 quarters · filed 2013-08-12 | $3.83M derived: sum of 4 quarters · filed 2013-08-12 | $7.15M 10-Q · filed 2012-08-09 | |||||||||||
| 2012-03-31 | -$1.72M 10-Q · filed 2013-05-15 | $2.20M derived: sum of 2 quarters · filed 2013-05-15 | $474.18K derived: sum of 3 quarters · filed 2013-05-15 | $3.49M derived: sum of 4 quarters · filed 2013-05-15 | $3.79M 10-Q · filed 2012-05-04 | |||||||||||
| 2011-12-31 | $3.92M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-28 | $2.19M derived: sum of 2 quarters · filed 2013-03-28 | $5.21M derived: sum of 3 quarters · filed 2013-03-28 | $4.83M 10-K · filed 2013-03-28 | $5.51M 10-K · filed 2012-03-09 | |||||||||||
| 2011-09-30 | -$1.72M derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06 | $1.29M derived: sum of 2 quarters · filed 2012-11-06 | $917.02K 10-Q · filed 2012-11-06 | $1.20M derived: sum of 4 quarters · filed 2012-11-06 | $1.59M 10-Q · filed 2011-11-07 | |||||||||||
| 2011-06-30 | $3.01M derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09 | $2.64M 10-Q · filed 2012-08-09 | $2.93M derived: sum of 3 quarters · filed 2012-08-09 | $2.26M derived: sum of 4 quarters · filed 2012-08-09 | $3.31M 10-Q · filed 2011-08-12 | |||||||||||
| 2011-03-31 | -$375.07K 10-Q · filed 2012-05-04 | -$89.30K derived: sum of 2 quarters · filed 2012-05-04 | -$750.94K derived: sum of 3 quarters · filed 2012-05-04 | |||||||||||||
| 2010-12-31 | $285.77K derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-09 | -$375.87K derived: sum of 2 quarters · filed 2012-03-09 | -$306.39K 10-K · filed 2012-03-09 | |||||||||||||
| 2010-09-30 | -$661.64K derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-07 | -$592.16K 10-Q · filed 2011-11-07 | ||||||||||||||
| 2010-06-30 | $69.48K 10-Q · filed 2011-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Marker Therapeutics, Inc. (MRKR) | United States | $0.020B | -2.86 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |
| Shuttle Pharmaceuticals Holdings, Inc. (SHPH) | United States | $0.019B | -0.31 |
| Rocket One Inc. (RKTO) | United States | $0.019B | |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| Biofrontera Inc. (BFRI) | United States | $0.018B | -2.13 |
| Lipocine Inc. (LPCN) | United States | $0.017B | -1.79 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| PALATIN TECHNOLOGIES INC (PTN) | United States | $0.017B | -5.36 |
| Allarity Therapeutics, Inc. (ALLR) | United States | $0.017B | -1.66 |